Suehiro Daiki, Ikeda Nami, Hirooka Kiyoto, Ihara Akinori, Fukami Ken, Ohnishi Motoko
San-ei Sucrochemical Co., Ltd., 24-5, Kitahama-machi, Chita-city 478-8503, Aichi, Japan.
Graduate School of Bioscience and Biotechnology, Chubu University, 1200, Matsumoto-cho, Kasugai-city 487-8501, Aichi, Japan.
Nutrients. 2025 Jan 12;17(2):262. doi: 10.3390/nu17020262.
BACKGROUND/OBJECTIVES: Facial bone density, including the jawbone, declines earlier than that of the lumbar spine and calcaneus. Calcium maltobionate is reported to mitigate bone resorption and maintain bone density of the lumbar spine in post-menopausal women, but its effects on facial bone density remain understudied. Therefore, this study compared variations in facial bone mineral density with variations in calcaneal bone mineral density and bone resorption markers among healthy women, examining differences between pre- and post-menopause and the effects of continuous calcium maltobionate intake.
This randomized, double-blind, placebo-controlled, parallel-group trial involved 48 healthy Japanese women aged 30-69 years, divided into two groups. The test food group received tablets containing calcium maltobionate, while the placebo group received tablets containing a maltose and calcium carbonate mixture for 24 weeks. Calcaneal and facial bone densities were measured pre- and post-intervention in both groups.
Post-intervention calcaneal bone mineral density and bone resorption marker deoxypyridinoline (DPD) showed no statistical difference between groups in pre-menopausal women. However, in post-menopausal women, the test food group exhibited significantly higher calcaneal bone density and lower DPD levels compared with the placebo group. Facial bone mineral density increased significantly in the test food group compared with the placebo group in post-menopausal participants, with similar trends observed in pre-menopausal participants.
Facial bone mineral density could serve as a useful indicator for monitoring bone health from middle age onward. Moreover, continuous calcium maltobionate intake appears to mitigate bone density decline in pre- and post-menopausal women, contributing to osteoporosis prevention (UMIN-CTR ID: 000046391).
背景/目的：包括颌骨在内的面部骨密度比腰椎和跟骨的骨密度更早下降。据报道，麦芽酮酸钙可减轻绝经后女性的骨吸收并维持腰椎骨密度，但其对面部骨密度的影响仍未得到充分研究。因此，本研究比较了健康女性面部骨矿物质密度的变化与跟骨骨矿物质密度和骨吸收标志物的变化，研究绝经前后的差异以及持续摄入麦芽酮酸钙的影响。
这项随机、双盲、安慰剂对照、平行组试验纳入了48名年龄在30 - 69岁的健康日本女性，分为两组。试验食品组服用含有麦芽酮酸钙的片剂，而安慰剂组服用含有麦芽糖和碳酸钙混合物的片剂，为期24周。两组在干预前后均测量了跟骨和面部骨密度。
绝经前女性干预后，两组之间的跟骨骨矿物质密度和骨吸收标志物脱氧吡啶啉（DPD）无统计学差异。然而，在绝经后女性中，试验食品组的跟骨骨密度显著高于安慰剂组，DPD水平则较低。与安慰剂组相比，绝经后参与者的试验食品组面部骨矿物质密度显著增加，绝经前参与者也观察到类似趋势。
面部骨矿物质密度可作为从中年起监测骨骼健康的有用指标。此外，持续摄入麦芽酮酸钙似乎可减轻绝经前和绝经后女性的骨密度下降，有助于预防骨质疏松症（UMIN-CTR ID：000046391）。
